[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

Kineta, Inc. (KANT) Form 4 filing dated 06/20/2025 details insider activity by director Marion R. Foote. On 06/17/2025 Foote exercised three series of warrants with a uniform strike price of $0.14, converting a total of 8,158 common shares.
• Warrants exercised: 3,457 shares (exp. 12/02/2025), 401 shares (exp. 04/03/2027) and 4,300 shares (exp. 06/01/2025).
• Transaction code “M” indicates the move was an option/warrant exercise rather than an open-market purchase.
• The exercise price of $0.14 appears in Table I, implying an aggregate cash outlay of roughly $1.1 K for the new shares.

Following the conversion, Foote’s direct beneficial ownership rises to 151,362 common shares; all three warrant positions are now fully extinguished (0 derivatives remaining). The form indicates no indirect holdings and no additional derivative instruments.

Implications for investors:

• Insider’s net long exposure increases, which can be interpreted as a vote of confidence, albeit modest in scale.
• The incremental dilution to outstanding share count is immaterial for most valuation models given the small share amount.

Positive

• Director increased direct ownership by 8,158 shares, signalling personal commitment to Kineta’s equity.
• All previously outstanding warrants (total 8,158 shares) now cleared, marginally reducing derivative overhang.

Negative

• None.

Insights

Financial Analyst

TL;DR: Small warrant exercise adds 8.1 K insider shares—confidence signal, but immaterial to valuation.

Director Marion R. Foote converted three low-strike warrants into 8,158 common shares at $0.14, raising ownership to 151,362 shares. The cash commitment is minor (~$1.1 K) and the share count impact negligible relative to Kineta’s float, so the market effect should be muted. Still, insiders rarely invest additional capital without at least a neutral-to-positive outlook, which can bolster sentiment. No open-market buying or new derivative grants were disclosed, suggesting housekeeping ahead of an upcoming warrant expiry rather than an opportunistic accumulation. Overall valuation or liquidity metrics remain unchanged.

Corporate Governance Expert

TL;DR: Routine insider warrant exercise, compliance intact, low governance impact.

The filing shows timely reporting under Section 16(a) with proper attorney-in-fact signature. Exercising soon-to-expire warrants before the 06/01/2025 series lapses reduces unexercised overhang and aligns director incentives with common shareholders. Because the exercise was contractual, not open-market, it poses minimal conflict-of-interest risk. No 10b5-1 plan box is checked, but transaction size is immaterial to control dynamics. Governance impact is therefore neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foote Marion R

(Last) (First) (Middle)

C/O KINETA, INC.

7683 SE 27TH STREET, SUITE 481

(Street)

MERCER ISLAND WA 98040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		M		8,158	A	$0.14	151,362	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (Right to Buy)	$0.14	06/17/2025		M			3,457	(1)	12/02/2025	Common Stock	3,457	$0	0	D
Warrants (Right to Buy)	$0.14	06/17/2025		M			401	(1)	04/03/2027	Common Stock	401	$0	0	D
Warrants (Right to Buy)	$0.14	06/17/2025		M			4,300	(1)	06/01/2025	Common Stock	4,300	$0	0	D

Explanation of Responses:

1. The warrants are immediately exercisable in full.

	/s/ Nanette Agustines, as Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Kineta (KANT) shares did Director Marion R. Foote acquire?

The filing shows Foote acquired 8,158 common shares through warrant exercises.

At what price were the warrants exercised?

Each warrant was exercised at $0.14 per share as indicated in Table I.

What is Marion R. Foote’s total shareholding after the transaction?

Foote now directly owns 151,362 Kineta common shares.

Were any derivative positions left after the exercise?

No. All three warrant series were fully exercised, leaving 0 derivative securities outstanding.

Does this Form 4 indicate open-market insider buying?

No. The transaction code "M" shows it was a warrant exercise, not an open-market purchase.